HRP20151006T1 - Terapeutska uporaba diaminofenotiazina - Google Patents

Terapeutska uporaba diaminofenotiazina Download PDF

Info

Publication number
HRP20151006T1
HRP20151006T1 HRP20151006TT HRP20151006T HRP20151006T1 HR P20151006 T1 HRP20151006 T1 HR P20151006T1 HR P20151006T T HRP20151006T T HR P20151006TT HR P20151006 T HRP20151006 T HR P20151006T HR P20151006 T1 HRP20151006 T1 HR P20151006T1
Authority
HR
Croatia
Prior art keywords
compound
daptz
crystalline
stable
reduced form
Prior art date
Application number
HRP20151006TT
Other languages
English (en)
Croatian (hr)
Inventor
Claude Michel Wischik
Damon Jude Wischik
John Mervyn David Storey
Charles Robert Harrington
Original Assignee
Wista Laboratories Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wista Laboratories Ltd. filed Critical Wista Laboratories Ltd.
Publication of HRP20151006T1 publication Critical patent/HRP20151006T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
HRP20151006TT 2007-10-03 2008-10-01 Terapeutska uporaba diaminofenotiazina HRP20151006T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96054407P 2007-10-03 2007-10-03
EP08806465.4A EP2205245B1 (en) 2007-10-03 2008-10-01 Therapeutic use of diaminophenothiazines
PCT/GB2008/003315 WO2009044127A1 (en) 2007-10-03 2008-10-01 Therapeutic use of diaminophenothiazines

Publications (1)

Publication Number Publication Date
HRP20151006T1 true HRP20151006T1 (hr) 2015-10-23

Family

ID=40220337

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20151006TT HRP20151006T1 (hr) 2007-10-03 2008-10-01 Terapeutska uporaba diaminofenotiazina

Country Status (16)

Country Link
US (3) US9149481B2 (https=)
EP (2) EP2205245B1 (https=)
JP (1) JP5592261B2 (https=)
CN (1) CN101883567B (https=)
AU (1) AU2008306688B2 (https=)
BR (1) BRPI0818182B1 (https=)
CA (2) CA2701075C (https=)
DK (2) DK2954932T3 (https=)
ES (2) ES2701089T3 (https=)
HR (1) HRP20151006T1 (https=)
HU (1) HUE025199T2 (https=)
MY (1) MY161656A (https=)
PL (2) PL2205245T3 (https=)
PT (2) PT2205245E (https=)
SI (2) SI2205245T1 (https=)
WO (1) WO2009044127A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2349322T7 (es) 2006-03-29 2019-10-17 Wista Lab Ltd Sales de 3,7-diamino-10H-fenotiazina y su utilización
CA2701075C (en) * 2007-10-03 2019-02-12 Wista Laboratories Ltd. Therapeutic use of diaminophenothiazines.
JP5868955B2 (ja) 2010-04-30 2016-02-24 プロセッタ アンチバイラル インコーポレイテッド 抗ウイルス化合物
JP6093707B2 (ja) 2010-11-30 2017-03-08 ウィスタ ラボラトリーズ リミテッド 化合物製剤
US20120244174A1 (en) 2011-01-31 2012-09-27 Intellect Neurosciences Inc. Treatment of tauopathies
JP5898701B2 (ja) 2011-02-11 2016-04-13 ウィスタ ラボラトリーズ リミテッド フェノチアジンジアミニウム塩およびそれらの使用
CN102690244A (zh) * 2011-03-22 2012-09-26 中国科学院上海生命科学研究院 调节α-突触核蛋白积聚的物质及其制药用途
EP2699241B1 (en) 2011-04-20 2016-07-27 Prosetta Antiviral Inc. Antiviral compounds
US20130315825A1 (en) * 2012-05-03 2013-11-28 Washington University Tricyclic heteroaromatic compounds as alpha-synuclein ligands
CN103864717B (zh) * 2014-04-04 2015-11-11 山东理工大学 一种针状亚甲基白晶体的制备方法
CN103923036B (zh) * 2014-04-24 2015-09-16 山东理工大学 一种棒状亚甲基蓝晶体的制备方法
CN105541756B (zh) * 2015-12-17 2018-02-09 陕西方舟制药有限公司 一种制备1‑(3,7‑双二甲氨基‑吩噻嗪‑10‑基)乙酮的方法
JP7073330B2 (ja) * 2016-07-25 2022-05-23 ウィスタ ラボラトリーズ リミテッド ジアミノフェノチアジンの投与及び投与量
GB201614834D0 (en) * 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
FI4385512T3 (fi) 2018-07-26 2026-01-12 Taurx Therapeutics Man Ltd Diaminofenotiatsiinien optimoitu annostus populaatioille
WO2020201828A1 (en) 2019-04-05 2020-10-08 Tauc3 Biologics Limited Anti-tauc3 antibodies and uses thereof
GB201909454D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Enhancers
GB201909493D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Therapeutic interactions
GB201909506D0 (en) 2019-07-02 2019-08-14 Wista Lab Ltd Synaptopathies
CN111956245A (zh) * 2020-08-27 2020-11-20 复旦大学附属肿瘤医院 术后认知功能障碍预防评估方法,系统和装置
AU2023279800A1 (en) 2022-05-31 2024-12-19 TauRx Therapeutics Management Ltd Treatment of neurodegenerative disorders utilising methylthioninium (mt)-containing compounds
EP4590306A1 (en) 2022-09-21 2025-07-30 Yin Sze Loh Oral formulation of diaminophenothiazines and methods of making and using the same in the treatment and/or prevention of diseases
WO2024163665A1 (en) * 2023-01-31 2024-08-08 Unlearn.AI, Inc. Systems and methods for prognostic covariate adjustment in logistic regression for randomized controlled trial design

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022788D0 (en) * 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
DE4140192C2 (de) * 1991-12-05 1996-02-29 Alfatec Pharma Gmbh Sol-gesteuerte Thermokolloidmatrix auf Gelatinebasis für perorale Retardformen
GB9506197D0 (en) 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
GB9710699D0 (en) 1997-05-24 1997-07-16 Danbiosyst Uk Gastro-retentive controlled release system
GB0017060D0 (en) * 2000-07-11 2000-08-30 Hunter Fleming Ltd Production, stabilisation and use of reduced forms of pharmaceutical compounds
GB0100119D0 (en) * 2001-01-03 2001-02-14 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0101049D0 (en) * 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0106953D0 (en) 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
US7410965B2 (en) * 2002-05-29 2008-08-12 Gruenenthal Gmbh Delayed release pharmaceutical composition containing 1-dimethyl-amino-3-(3-methoxyphenyl)-2-methyl-pentan-3-ol
GB0322756D0 (en) 2003-09-29 2003-10-29 Univ Aberdeen Methods of chemical synthesis
CN101084204B (zh) * 2004-09-23 2012-12-05 卫思道制药有限公司 包括亚甲蓝(mtc)在内的二氨基吩噻嗪鎓化合物的化学合成和纯化方法
WO2006091728A2 (en) * 2005-02-24 2006-08-31 The Trustees Of The University Of Pennsylvania Microtubule stabilizing compounds and methods of their use
WO2007056439A1 (en) * 2005-11-08 2007-05-18 Collegium Pharmaceutical, Inc. Salts of methylene blue and its derivatives
ES2349322T7 (es) * 2006-03-29 2019-10-17 Wista Lab Ltd Sales de 3,7-diamino-10H-fenotiazina y su utilización
SI2004155T1 (en) * 2006-03-29 2018-05-31 Wista Laboratories Ltd. Inhibitors of protein aggregation
MY148145A (en) * 2006-07-11 2013-03-15 Wista Lab Ltd Methods of synthesis and/or purification of diaminophenothiazinium compounds
AU2008265045B2 (en) * 2007-06-19 2014-02-27 Taurx Therapeutics Management Ltd. Phenothiazine compounds for treating Mild Cognitive Impairment
CA2701075C (en) * 2007-10-03 2019-02-12 Wista Laboratories Ltd. Therapeutic use of diaminophenothiazines.

Also Published As

Publication number Publication date
SI2954932T1 (sl) 2019-01-31
CN101883567A (zh) 2010-11-10
JP5592261B2 (ja) 2014-09-17
CA3027974A1 (en) 2009-04-09
HUE025199T2 (en) 2016-01-28
EP2954932B1 (en) 2018-09-19
ES2546819T3 (es) 2015-09-28
JP2010540606A (ja) 2010-12-24
US20100290986A1 (en) 2010-11-18
PL2954932T3 (pl) 2019-04-30
PL2205245T3 (pl) 2015-12-31
CA2701075A1 (en) 2009-04-09
EP2205245A1 (en) 2010-07-14
US20190151329A1 (en) 2019-05-23
SI2205245T1 (sl) 2015-10-30
US9149481B2 (en) 2015-10-06
CA3027974C (en) 2022-03-15
AU2008306688B2 (en) 2014-05-22
HK1211889A1 (en) 2016-06-03
HK1140675A1 (en) 2010-10-22
EP2954932A1 (en) 2015-12-16
US20160030444A1 (en) 2016-02-04
DK2205245T3 (en) 2015-09-28
EP2205245B1 (en) 2015-06-24
WO2009044127A1 (en) 2009-04-09
US10188658B2 (en) 2019-01-29
BRPI0818182B1 (pt) 2021-10-19
MY161656A (en) 2017-04-28
BRPI0818182A2 (pt) 2020-06-23
ES2701089T3 (es) 2019-02-20
CN101883567B (zh) 2012-12-26
PT2205245E (pt) 2015-10-13
CA2701075C (en) 2019-02-12
AU2008306688A1 (en) 2009-04-09
PT2954932T (pt) 2018-12-12
DK2954932T3 (en) 2018-12-17

Similar Documents

Publication Publication Date Title
HRP20151006T1 (hr) Terapeutska uporaba diaminofenotiazina
JP2010540606A5 (https=)
IT1266565B1 (it) Composizioni farmaceutiche a rilascio controllato a base di uno o piu' sali farmaceuticamente accettabili dell'acido gamma-idrossi-butirrico.
SI2004155T1 (en) Inhibitors of protein aggregation
DK1205190T3 (da) Stabile medicinalsammensætninger til oral administration og med anvendelse af ferrioxider
DE69212882D1 (de) Gallensäuresalze enthaltende magenstabile pharmazeutische Zusammensetzung zur oralen Verabreichung
EP3689346B1 (en) 3,6-disubstituted xanthylium salts for treating tauopathies
YU9194A (sh) Derivati pipolo-piridina
PT2057136E (pt) Processos de síntese e/ou purificação de compostos diaminofenotiazínio
NO20020180D0 (no) Nye kinuklidinderivater og medisinske sammensetninger inneholdende det samme
ATE14423T1 (de) Hydroxamsaeurederivate vom typ der mannich-basen mit verbesserter biologischer verfuegbarkeit von nicht-steroiden entzuendungshemmern, verfahren zur herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzung.
BR9510410A (pt) Composto, composição farmacêutica ou veterinária, processo para produzir o composto e uso do composto
ATE14884T1 (de) S-adenosinylmethionine-derivate, verfahren zu ihrer herstellung und die pharmazeutischen zusammensetzungen welche als aktive substanz diese derivate enthalten.
ES2314593T3 (es) Forma cristalina alfa de ranelato de estroncio, su procedimiento de preparacion y composiciones farmaceuticas que la contienen.
ATE344240T1 (de) Kondensierte heterozyklische verbindungen und ihre pharmazeutische anwendung
DE3174554D1 (en) Substituted pyrimidin-2-ones, the salts thereof, processes for their preparation, and pharmaceutical compositions containing them
MY138865A (en) New tricyclic azepine compounds, a process for their preparation and pharmaceutical compositions containing them
ATE16278T1 (de) Hydroxybenzylamino-aryl verbindungen, verfahren zur deren herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen.
ZA933455B (en) Thiochroman compounds, processes for the preparation thereof and pharmaceutical compositions containing them
ATE330956T1 (de) Bizyklisch substituierte 4- aminopyridopyrimidinderivate
ATE80881T1 (de) Heteroarotinoid-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen.
JPS5942315A (ja) 下痢治療用薬剤
YU81101A (sh) Polimorfni oblici kristalnog citrata azabiciklo (2,2,2) oktan-3-amina i njihovih farmaceutskih kompozicija
DE69300197D1 (de) Aminoalkylchromone, Verfahren zu ihrer Herstellung und diese enthaltende Zusammensetzungen.
DE68905361D1 (de) Trienische derivate mit chromenischer struktur, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen.